Manuscript

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Posted on

AUTHORS: Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber […]

Poster

Benefits and Risks of Clopidogrel Versus Aspirin Monotherapy for Acute Ischemic Stroke: A Systematic Review and Meta-analysis

Posted on

AUTHORS: Shalini G., Min L., Bo H., Liping L., Dara P., Toby S. CONFERENCE: ESC 2018 DATE: April 11-13, 2018. Objective(s): To conduct a systematic literature review to compare the efficacy and safety of clopidogrel versus aspirin monotherapy in patients with acute ischemic stroke.   See poster 2018-ESC-DRE-Sanofi-Poster

Poster

Prevalence and Timing of De-Escalation Therapy from Ticagrelor to Clopidogrel in Acute Coronary Syndrome Patients: Results of a Meta-Analysis

Posted on

AUTHORS: Angiolillo D, Paek D, Shah R, Sayre T, Clausel A, Girotra S CONFERENCE: ADA 2018 DATE: March 10-12, 2018. Aim: To conduct a systematic literature review to assess the prevalence rate of de-escalation from ticagrelor to clopidogrel in patients with ACS and to assess the time at which de-escalation takes place following the index event. 2018-ACC-DRE-Sanofi-UF-Poster […]

Poster

Real-World Incidence of Malignancies, Infections and Auto-Immune Diseases in Persons with Rheumatoid Arthritis Treated with Biological vs. Non-Biological Disease-Modifying Antirheumatic Drugs: A systematic Review and Meta-Analysis

Posted on

AUTHORS: Simon T., Kostelec J., Franek J. CONFERENCE: 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management ICPE 2017 DATE: August 26-30, 2017. Objective(s): To perform a systematic literature review to identify publications reporting the rate of malignancies, autoimmune diseases, and infections for BDMARDs vs. NBDMARDs To determine the comparative incidence of immune-related events through meta-analysis See poster […]